Mechanism of enzymatic degradation of the azo dye Orange II determined by ex situ 1H nuclear magnetic resonance and electrospray ionization-ion trap mass …

C López, AG Valade, B Combourieu, I Mielgo… - Analytical …, 2004 - Elsevier
Removal of azo dye effluents generated by textile photography industries is a main issue in
wastewater treatment. Enzymatic treatment of dyes appears to be one of the most efficient …

[HTML][HTML] Crystal structure of dopamine D1 receptor in complex with G protein and a non-catechol agonist

…, I Fish, S Lovera, ZA Sands, S Kelm, A Valade… - Nature …, 2021 - nature.com
Dopamine D1 receptor (D1R) is an important drug target implicated in many psychiatric and
neurological disorders. Selective agonism of D1R are sought to be the therapeutic strategy …

Evaluation of 18F-UCB-H as a novel PET tracer for synaptic vesicle protein 2A in the brain

…, N Mestdagh, T Buchanan, A Valade… - Journal of Nuclear …, 2014 - Soc Nuclear Med
Synaptic vesicle protein 2 isoforms are critical for proper nervous system function and are
involved in vesicle trafficking. The synaptic vesicle protein 2A (SV2A) isoform has been …

Novel Strategies To Activate the Dopamine D1 Receptor: Recent Advances in Orthosteric Agonism and Positive Allosteric Modulation

A Hall, L Provins, A Valade - Journal of medicinal chemistry, 2018 - ACS Publications
The five dopamine receptor subtypes (D 1–5 ) are activated by the endogenous catecholamine
dopamine. Sustained research has sought to identify selective ligands for receptor …

Discovery of heterocyclic nonacetamide synaptic vesicle protein 2A (SV2A) ligands with single‐digit nanomolar potency: opening avenues towards the first SV2A …

…, N Price, Y Quesnel, X Sauvage, A Valade… - …, 2014 - Wiley Online Library
The role of the synaptic vesicle protein 2A (SV2A) protein, target of the antiepileptic drug
levetiracetam, is still mostly unknown. Considering its potential to provide in vivo functional …

Measuring brain synaptic vesicle protein 2A with positron emission tomography and [18F]UCB‐H

…, C Bastin, G Becker, J Mercier, A Valade… - … Research & Clinical …, 2017 - Wiley Online Library
Introduction Brain distribution of synaptic vesicle protein 2A was measured with fluorine‐18
UCB‐H ([ 18 F]UCB‐H) and positron emission tomography (PET). Methods Images of …

Discovery and development of SV2A PET tracers: potential for imaging synaptic density and clinical applications

J Mercier, L Provins, A Valade - Drug Discovery Today: Technologies, 2017 - Elsevier
Imaging synaptic density in vivo has promise for numerous research and clinical applications
in the diagnosis and treatment monitoring of neurodegenerative and psychiatric diseases. …

Primary amino acid derivatives: Compounds with anticonvulsant and neuropathic pain protection activities

…, M De Ryck, R Kaminski, A Valade… - Journal of medicinal …, 2011 - ACS Publications
Pharmacological management remains the primary method to treat epilepsy and neuropathic
pain. We have advanced a novel class of anticonvulsants termed functionalized amino …

[HTML][HTML] Preclinical radiation dosimetry for the novel SV2A radiotracer [18F]UCB-H

…, J Aerts, N Mestdagh, T Buchanan, A Valade… - EJNMMI research, 2013 - Springer
Background [ 18 F]UCB-H was developed as a novel radiotracer with a high affinity for synaptic
vesicle protein 2A, the binding site for the antiepileptic levetiracetam. The objectives of …

Thiophosphorylated cavitand: structure and affinity towards soft metal ions

B Bibal, JP Declercq, JP Dutasta, B Tinant, AG Valade - Tetrahedron, 2003 - Elsevier
The iiii stereoisomer of the tetrathiophosphonate-calix[4]resorcinarene host 1 exhibited
excellent extraction properties towards soft metal ions, with a better affinity for Ag + (91%), than …